Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 7 of 7 entries
View as:

Milademetan in Advanced/Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05012397 Org: User:
Start: 11/01/21 End: 10/15/23 Due: 10/15/24

Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Phase: N/A Priority: Normal
NCT ID: NCT02449681 Org: User:
Start: 08/31/15 End: 01/31/17 Due: 01/31/18

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Phase: N/A Priority: Normal
NCT ID: NCT06090318 Org: User:
Start: 05/19/23 End: 05/30/23 Due: 05/30/24

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

Phase: N/A Priority: Normal
NCT ID: NCT02454842 Org: User:
Start: 06/30/15 End: 01/31/17 Due: 01/31/18

Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma

Phase: N/A Priority: Normal
NCT ID: NCT04979442 Org: User:
Start: 07/14/21 End: 10/01/23 Due: 10/01/24

A Study of Milademetan Administration on Cardiac Repolarization in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05758818 Org: User:
Start: 04/17/23 End: 06/08/23 Due: 06/08/24

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

Phase: N/A Priority: Normal
NCT ID: NCT03805841 Org: User:
Start: 03/13/19 End: 04/23/21 Due: 04/23/22